Jeremy Chartash, OD
Optometrist · Sandy Springs, GANPI 1568903680
Payments from drug & device makers
Across 145 payments — averaging $26.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bausch & Lomb Americas Inc.$672
- AbbVie$599
- Sun Pharmaceutical Industries Inc.$390
- Oyster Point Pharma, Inc.$296
- Notal Vision, Inc.$221
- Johnson & Johnson Vision Care, Inc.$206
- plus $1K from 17 others
What the payments were for
- Speaking & faculty fees$2216%
- Food & beverage$3,60894%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bausch & Lomb Americas Inc. | 27 | $672 |
| AbbVie(2 entities) | 31 | $599 |
| Sun Pharmaceutical Industries Inc. | 11 | $390 |
| Oyster Point Pharma, Inc. | 9 | $296 |
| Notal Vision, Inc. | 1 | $221 |
| Johnson & Johnson Vision Care, Inc. | 10 | $206 |
| Alcon | 8 | $197 |
| Sight Sciences, Inc. | 2 | $150 |
| Tarsus Pharmaceuticals, Inc. | 5 | $133 |
| Coopervision Inc. | 4 | $131 |
| Harrow Eye, LLC | 4 | $120 |
| Dompe US, Inc. | 5 | $113 |
| Novartis | 5 | $109 |
| Amgen | 4 | $97 |
| Kala Pharmaceuticals, Inc. | 5 | $78 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 3 | $67 |
| Biotissue Holdings Inc. | 3 | $58 |
| Shire North American Group Inc | 2 | $52 |
| Glaukos Corporation | 2 | $47 |
| Johnson & Johnson Surgical Vision, Inc. | 1 | $32 |
| Visioneering Technologies, Inc. | 1 | $23 |
| Rxsight Inc | 1 | $21 |
| Ocular Therapeutix, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TearCare SmartLid$128
- TEARCARE(TM) (2.2) SYSTEM KIT$128
- TYRVAYA$126
- CEQUA$114
How this compares
$3,829 in reported general payments places this provider in the 85th percentile of 1,285 optometrist providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 17 | $25,782 |
| LumiganBimatoprost | 19 | $12,860 |
| XiidraLifitegrast | 14 | $11,510 |
| EysuvisLoteprednol Etabonate | 22 | $10,886 |
| RocklatanNetarsudil Mesylat/Latanoprost | 17 | $6,056 |
| CombiganBrimonidine Tartrate/Timolol | 16 | $4,299 |
| Loteprednol Etabonate | 21 | $2,455 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 11 | $1,787 |
| Latanoprost | 146 | $1,235 |
| Brimonidine Tartrate | 12 | $1,151 |
| Prednisolone Acetate | 22 | $730 |
| Tobramycin-DexamethasoneTobramycin/Dexamethasone | 19 | $705 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 37 | $510 |
| Timolol Maleate | 60 | $302 |
| Doxycycline Hyclate | 31 | $301 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan, Combigan | $599 | $42,94152 claims |
| Bausch & Lomb Americas Inc.Xiidra | $672 | $11,51014 claims |
| Kala Pharmaceuticals, Inc.Eysuvis | $78 | $10,88622 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate | $67 | $2,45521 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,285 optometrist providers in Georgia.
Other optometrist in Sandy Springs
- George ShidaSandy Springs$13K
- Christina LockeSandy Springs$13K
- Anne BrobstDuluth$1.2M
- Michael HungCumming$1.2M
- Joshua JohnstonAtlanta$997K
- John WomackCanton$931K
- David WinnerRoswell$877K
- Lauren HackerGreensboro$511K
- Katherine WooAtlanta$336K
- Naheed AhmadRoswell$296K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.